Subject: OutcomefResults of the meeting of the Board of Directors of the Company held on 16 th May, 2018

Size: px

Start display at page:

Download "Subject: OutcomefResults of the meeting of the Board of Directors of the Company held on 16 th May, 2018"

Darren Powers
5 years ago
Views:

1 .. ~ Date: 16/05/2018 To, National Stock Exchange of India Ltd. Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai Tel No: (022) Fax No: (022) Symbol: MOREPENLAB BSE Limited Floor 25, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai Phones: /4 Fax: Scrip Code: Subject: OutcomefResults of the meeting of the Board of Directors of the Company held on 16 th May, 2018 Dear Sir, This is to inform you that the Board of Directors of the Company, in their meeting held on Wednesday, 16 th May, 2018 (Timings: Meeting commenced at Noon and concluded at 2.10 p.m.), have inter-alia considered and approved the Audited Standalone and Consolidated Financial Results of the Company for the Quarter and Financial Year ended 31 st March, 2018, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, A copy of the 'Results' alongwith the Report of the Auditors of the Company, with unmodified opinion, thereon and a declaration to that effect is enclosed herewith. Kindly acknowledge the receipt and take it on your record. Encl.: As Above Morepen Laboratories Limited Corp. Off.: 4th Floor,Antnksh Bhawan, 22 K.G.Marg, New Delhi , INDIA Tel.: , , corporate@morepen.com.website: CIN NO. L24231 HP1984PLC Plant & Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (HP.) Tel.: , , Fax: , . plants@morepen.com

2 Morepen Laboratories Limited CIN L2423Ull'1984PLCOO6028 Statement of Standalone Audited Financial Results For the Ouarter and Year Ended March (Rs.in Lakhs Particulars ( uarter Ended Year Ended I Revenue from operations (Unaudited) Ref Not 8 Ref Note 8 Revenue from operations (Net) Other Income Total Revenue Expenses a) Cost of Material Consumed b) Purchase of stock- in. trade c) Changes in inventories of Finished goods, Work -in- progress and Stock-in-trade ,44410) d) Employee Benefits Expenses e) Finance Cost f) Depreciation and Amortisation g) Power and Fuel h) Tra velling Expenses i) Selling and Distribution Expenses j) Other Expenses Total Expenses Profit before Exceptional Items & Tax (1-2) Exceptional Items - Income/ (Expense) - 5 Profit before Tax (3-4) Income Tax 7 Net Profit for the period (5-6) Other Comprehensive Income (3.36) ( Total Comprehensive Income Paid-up Equity Share Capital of Face Value ofrs.2/ II Reserves excluding Revaluation reserve a) Earning Per Share (in Rs.) Basic & Diluted The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 16,2018. The statutory Auditors have carried out the Audit for the year ended March 31, The Company is engaged in the Pharmaceutical Business Segment. 3. The Company has adopted Indian Accounting Standard (Ind AS) prescribed under section 133 of the Companies act, 2013, read with the relevant rules issued thereunder, from April 01,2017, with transition date of April 01, The figures for the quarter and year ended are in Compliance with Ind AS. 4. In the matter of scheme of arrangement and compromise uls 391 of the Companies Act, 1956, the Hon'ble High Court at Shimla accorded its approval vide order dt.august 4,2009. On an appeal filed by the Union Government, the Division bench remanded the matter back to the single judge, so as to give a hearing to the Central Government and decide the matter afresh. Subsequently this matter was transferred to Hon'ble National Company Law Tribunal (NCLT), Chandigarh, which rejected the scheme. On an appeal filed by the Company before Hon'ble National Company Law Appellate Tribunal (NCLAT), the Hon'ble NCLAT while issuing notice has stayed the operation of the NCL T's order dated Due to carried forward losses, no provision for taxes is required to be made during the year. 6. Current quarter expesnses ofrs Lakhs (YTD Rs Lakhs) will be amortised in the future periods as benefits arising out of this spend are expected to accrue over more than one year. 7. The figures of the previous period have been re-grouped/re-classified to conform to the current period's classification. 8. The figures for the quarter ended March 31, 2018 and March 31, 2017 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year to date figures upto the third quarter ended December 31,2017 and December 31, Reconciliation of the net profit for the quarter ended March 31, 2017 onder Indian GAAP (Previous GAAP) and Ind AS is as under: IRs./Lakhs) Particular Quarter YearEnded #1l Ended Net Profit for the Quarter/period as per Previous GAAP Add/(Less)-AdjustmentforGAAP Differences- ;-J» I~Goyalcf (Acturial gain)/loss on defined benefits plan reclassified to OCl (6.55) ;: 0 cjy~~ N' 0 ; 7334N ~

3 Impact of reclassification of Redeemable Preference Shares as Debt (48.75) (48.75) as uer Ind AS - Provision of cumulative dividend thereon Others (2.36) (0.36) Net Profitforthe quarter/year as per Ind AS , Reconciliation of Equity as previously reported on account of transition from previous Indian GAAP to Ind AS for the year ended March 31, 20I7 is as under: (Rs.z l.akhs) Particular Year Ended Equity as on March 31, 2017 as per Previous GAAP Add/(Less)-AdjustmentforGAAP Differences Irnpact of reclassification of Redeemable Preference Shares as Debt (782.94) as per Ind AS -Provisionof cum mula live dividend thereon Others (7.84) Equityas on March31,2018asperindAS 13, II. Statement of Assets and Liabilities: Particulars Year ended 31.03, A ASSETS I Non Current Assets (a) Property, Plant and Equipment (b) Goodwill (c) Other Intangible Assets Financial Assets : (a) Investments (b) Loans (c) Other Non-Current Assets Non- Current Assets 35985, Current Assets (a) Inventories Financial Assets : (a) Investments (b) Trade receivables (c) Cash and cash equivalents (d) Bank Balance other than Cash and Cash Equivalents (e) Loan (f) Other Current Assets Current Assets Total B EQUITY AND LIABILITIES I EQUITY (a) Equity Share Capital (b) Other Equity Equity & Liabilities Non - Current Liabilities Financial Liabilities' (a) Borrowings (b) Other Financial Liabilities (c) Provisions Non- Current Liabilties Current Liabilities Financial Liabilities: (a) Trade Payables (b) Other Financial Liabilities (c) Other current liablilities (d) Provisions Current Liabilties Total For and on behalf of the Board of Directors of Morepe ~~Limited Place: New Delhi Date. May 16,2018!~'") - ~ GOYal ~~~"'~P C ha ir.,,&."""""';"~ ~~ I~ 0 CJj RN. l-q 02 N 0'-".:<1 Kv" - rf

4 506, Ambadeep Building, 14, K G Marg New Delhi Ph.: mail: satindergoyalandco@gmail.com Satinder Goyal & Co. Chartered Accountants Auditor's Report on Quarterly Financial Results and Year to date results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 To Board of Directors of Morepen Laboratories Limited We have audited the accompanying Standalone financial results ("the statement") of Morepen Laboratories Limited ("the Company") for the quarter and year ended March 31, 2018, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, Attention is drawn to the fact that the figures for the quarter ended 31 March 2018 and the corresponding quarter ended in the previous year as reported in the statement are the balancing figures between audited figures in respect of full financial year and the published year to date figures up to the end of the third quarter. The Statement has been prepared on the basis of the annual financial statements and reviewed quarterly financial results up to the end of third quarter which are the responsibility of the Company's management. Our responsibility is to express an opinion on the statement based on our audit of financial statements, which have been prepared in accordance with the recognition and measurement principles laid down under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India; and in compliance with requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the statement is free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed in financial results. An audit also includes assessing the accounting principles used and significant estimates made by the management. We believe that our audit provides a reasonable basis for our opinion. The comparative financial information of the company for the corresponding quarter and year ended March 31, 2017 included in these financial results, are based on the previously issued financial results prepared in accordance with the recognition and measurement principles specified under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India and audited by the previous auditor whose report for the year ended March 31, 2017 dated April 29, 2017 expressed an unmodified opinion on those financial statements. ~'?,~GOYal cf. i~frn (.0* * N)(I) 9 c: Ol,?: ~ (9/"ed ACCo'S

5 In our opinion and to the best of our information and according to the explanations given to us, the accompanying statement: (i) is presented in accordance with the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, in this regard and; (ii) give a true and fair view of the net profit and other financial information for the quarter and year ended March 31, Date: 16th May 2018 Place: New Delhi

6 Morepen Laboratories Limited CIN- L24231HP1984PLC Statement of Consolidated Audited Financial Results Forthe Year Ended March Year Ended ffi.s.in Lakhs Particulars 31.03_ I Revenue from operations Revenue from operations (Net) Other Income Total Revenue 2 Expenditure a) Cost of Material Consumed b) Purchase of stock - in - trade c) Changes in inventories of Finished goods, Work -in- progress and Stock-in-trade ( ) d) Employee Benefits Expenses e) Finance Cost f) Depreciation and Amortisation g) Power and Fuel h) Travelling Expenses i) Selling and Distribution Expenses j) Other Expenses Total Expenditure Profit before Exceptional Items & Tax (1-2) Exceptional Items - Income/(Expense) 5 Profit before Tax (3-4) Income Tax 7 Net Profit for the period (5-6) Share of minority interest in Profit/ Loss ( Net Profit after minority interest Other Comprehensive Income 8.87 ( Total Comprehensive Income Paid-up Equity Share Capital of Face Value ofrs.2/- each Reserves excluding Revaluation reserve a) Earning Per Share (in Rs.) Basic & Diluted The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 16, The statutory Auditors have carried out the Audit for the year ended March 31, The Company is engaged in the Pharmaceutical Business Segment. 3. The Company has adopted Indian Accounting Standard (lnd AS) prescribed under section 133 of the Companies act, 2013, read with the relevant rules issued thereunder, from April 01, 2017, with transition date of April 01,2016. The figures for the quarter and year ended are in Compliance with Ind AS. 4. Reconciliation of the net profit for the quarter ended March 31,2017 under Indian GAAP (Previous GAAP) and Ind AS is as under: Rs.lLakhs\ Particular Year Ended Net Profit for the quarter/period as per Previous GAAP Add/'(Less). Adjustment for GAAP Differences- (Acturial gain)/loss on defmed benefits plan reclassified to OCI Impact of reclassification of Redeemable Preference Shares as Debt as per lnd AS (48.75) Provision of cumulative dividend thereon Others (0.34) Net Profit for the quarter/veer as per lnd AS 2.363,P2 ~

7 5. Reconciliation of Equity as previously reported on account of transition from previous Indian GAAP to Ind AS for the for the year ended March 31,2017 is as under: - (Rs.lLakhs) Particular Year Ended Equity as on March 31, 2017 as per Previous GAAP Add/(Less)- Adjustment for GAAP Differences Impact of reclassification of Redeemable Preference Shares as Debt as per Ind AS (782.94) Provision of cummulative dividend thereon Others (7.84) Eauitv as on March 31, 2018 as oer Ind AS 10, The figures of the previous period have been re-grouped/re-classified to conform to the current period's classification. 7. Statement of Assets and Liabilities: Particulars Year ended A ASSETS I Non Current Assets (a) Property, Plant and Equipment (b) Goodwill , (c) Other Intangible Assets 1, Financial Assets: (a) Loans (b) Other Non-Current Assets Non- Current Assets 33867, Current Assets (a) Inventories Financial Assets : I(a) Investments (b) Trade receivables (c) Cash and cash equivalents (d) Bank Balance other than Cash and Cash Equivalents (e) Loan (I) Other Current Assets Current Assets TOTAL B EQUITY AND LIABILITIES I EQUITY (a) Equity Share Capital (b) Other Equity Equity & Liabilities MINORITY INTEREST (45.42) (63.37) 3 Non - Current Liabilities Financial Liabilities: (a) Borrowings (b) Other Financial Liabilities (c) Provisions Non- Current Liabilties Place: New Delhi 4 Current Liabilities Financial Liabilities: (a) Trade Payables (b) Other Financial Liabilities (c) Other current liablilities (d) Provisions Current Liabilties (Sushi! Suri) TOTAL p~~ For and on behalf of the Board of Directors of More pen Laboratories Limited Date: Mav 16, 2018 Chairman & Manazina Direttorll - \... --===--/ -- --

8 506, Ambadeep Building. 14, K G Marg New Delhi-11000l Ph.: mail: satindergoyalandco@grnail.com Satinder Goyal & Co. Chartered Accountants Independent Auditor's Report To the Board of Directors of Morepen Laboratories Limited We have audited the accompanying statement of consolidated financial results of Morepen Laboratories Limited ("the Holding Company") and its subsidiaries (the holding company and its subsidiaries together referred to as "the Group") for the year ended March 31, 2018, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, This statement, which is the responsibility of the Holding Company's management and approved by the board of directors, has been compiled from the related consolidated financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the statement based on our audit of such consolidated financial statements. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the statement is free from material misstatements. An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the statements. The procedures selected depend on the auditor' judgement, including the assessment of the risk of material misstatement of the statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the company's preparation and fair representation of the statement in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the management, as well as evaluating the overall presentation of the statement. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion. We did not audit the financial statement of subsidiary viz.: Morepen Inc. included in consolidated financial results whose financial statements reflect total assets of Rs lakhs as at March 31, 2018, total revenue of Rs lakhs, total profit after tax of Rs. 3 L69 lakhs and total comprehensive income of Rs lakhs for the year ended on that date, as considered in the consolidated financial results. These.financial statements have been audited by other auditors whose report has been furnishe ~tjj., e management and our opinion :. ' <? c3 ~N oj( * V N /", (1 ~~ 'I:- ted A~Co

9 on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the reports of the other auditors. The comparative financial information of the company for the year ended March 31, 2017 included in these financial results, are based on the previously issued financial results prepared in accordance with the recognition and measurement principles specified under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India and audited by the previous auditor whose report for the year ended March 31, 2017 dated April 29, 2017 expressed an unmodified opinion on those financial statements. In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the report of the other auditor referred to above, the statement: (i) in the case of the consolidated financial results of the group includes the results for the year ended March 31,2018 of the following entities: a. Morepen Laboratories Limited b. Dr. Morepen Limited c. Total Care Limited d. Morepen Inc. (ii) is presented in accordance with the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, in this regard, and; (iii) gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated net profit, total comprehensive income and other financial information of the group for the year ended March 31, For Satinder Goyal & Co. Chartered Accountants Firm's Regn. No: N Date: 16th May 2018 Place: New Delhi S.K Goyal (Partner) Membership No. :

10 ..."~ Date: 16/05/2018 To, National Stock Exchange of India Ltd. Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai Tel No: (022) Fax No: (022) Symbol: MOREPENLAB BSE Limited Floor 25, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai Phones: /4 Fax: Scrip Code: Subject: Declaration under Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 DECLARATION In compliance with the provisions of Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that M/ s. Satinder Goyal & Co., Chartered Accountants (FRN N), Statutory Auditors of the Company have issued an Audit Report with unmodified opinion on Audited Standalone and Consolidated Financial Results of the Company for the Quarter and Financial Year ended 31 st March, Kindly take note of the same. Thanking you. Yours faithfully, For Morepen Laboratories Limited (Ajay Sharma) Chief Financial Officer Morepen Laboratories Limited Corp. Off.: 4th Floor,Antnksh Bhawan, 22 K.G.Marg. New Delhi INDIA Tel.: , corporate@morepen com.vvebsite. com CIN NO. L24231 HP1984PLC Plant & Regd. Off.. Morepen Village. Malkumajra. Nalagarh Road. Baddi, Dislt. Solan (H.P.) Tel.: Fax: plants@morepen.com

BEACH RESORT VAR CA, GOA

BEACH RESORT VAR CA, GOA CARAVELA@ BEACH RESORT May 17, 2018 VAR CA, GOA BSE Limited Corporate Compliance Department Rotunda Building P. J. Towers, Dalal Street, Fort Mumbai 400001 Scrip Code - 523269 The National Stock Exchange